Company Cingulate Inc.

Equities

CING

US17248W2044

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-25 EDT			5-day change	1st Jan Change
0.586 ^USD	-3.46%		+2.81%	-92.34%

05-21	FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD	CI
05-08	Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Companyâs CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

Number of employees: 13

Managers	Title	Age	Since
Matthew Brams FOU	Founder	61	12-12-31
Raul Silva FOU	Founder	67	12-12-31
Shane Schaffer CEO	Chief Executive Officer	49	12-12-31
Jennifer Callahan DFI	Director of Finance/CFO	53	16-12-31
Laurie Myers COO	Chief Operating Officer	67	17-03-31
Thomas Dalton IRC	Investor Relations Contact	-	21-03-31

Members of the board	Title	Age	Since
Peter Werth BRD	Director/Board Member	85	18-05-31
Jeffrey Ervin BRD	Director/Board Member	46	02-12
Shane Schaffer CEO	Chief Executive Officer	49	12-12-31
John Roberts BRD	Director/Board Member	65	02-12

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,227,577	4,955,592 ( 79.57 %)	0	79.57 %

Name	Equities	%	Valuation
Peter Werth 18.90 %	1,177,018	18.90 %	825 090 $
Lind Global Fund II LP 4.528 %	282,000	4.528 %	197 682 $
Cowen & Co. LLC 1.525 %	95,000	1.525 %	66 595 $
Shane Schaffer 0.6819 %	42,467	0.6819 %	29 769 $
Matthew Brams 0.5221 %	32,512	0.5221 %	22 791 $
Raul Silva 0.3751 %	23,362	0.3751 %	16 377 $
HRT Financial LLC 0.1716 %	10,689	0.1716 %	7 493 $
Craig Gilgallon 0.1564 %	9,742	0.1564 %	6 829 $
Tower Research Capital LLC 0.1298 %	8,084	0.1298 %	5 667 $
Louis van Horn 0.1257 %	7,831	0.1257 %	5 490 $

Name	Equities	%	Valuation
Sabby Management LLC -	468,722	-	8 906 $
Altium Capital Management LP -	270,000	-	5 130 $
Hudson Bay Capital Management LP -	210,798	-	4 005 $
Warberg Asset Management LLC -	43,155	-	820 $
Armistice Capital LLC -	20,500	-	390 $
GoalVest Advisory LLC -	3,000	-	57 $
BofA Securities, Inc. -	2,653	-	50 $
UBS Securities LLC -	86	-	2 $

Cingulate, Inc.

1901 West 47th Place

66205, Kansas City

http://www.cingulate.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.586 USD

Average target price

14 USD

Spread / Average Target

+2,289.08%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CINGULATE INC.	-92.34%	4.05M
MODERNA, INC.	+38.36%	52.73B
LONZA GROUP AG	+38.82%	39B
IQVIA HOLDINGS INC.	-8.63%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	30.38B
CELLTRION, INC.	-11.17%	26.39B
ICON PUBLIC LIMITED COMPANY	+11.44%	26.08B
UNITED THERAPEUTICS CORPORATION	+45.09%	14.15B
MEDPACE HOLDINGS, INC.	+32.93%	12.6B
BIO-TECHNE CORPORATION	-5.30%	11.51B

Other Biotechnology & Medical Research